| Karleen Tichy, | |
|
809 Elm St, Suite 1200, Alexandria, MN 56308-5296 | |
| (320) 763-6018 | |
| (320) 763-4127 |
| Full Name | Karleen Tichy |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Community Health |
| Location | 809 Elm St, Alexandria, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497295414 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WC1500X | Registered Nurse - Community Health | R173353-8 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karleen Tichy, 809 Elm St, Suite 1200, Alexandria, MN 56308-5296 Ph: (320) 763-6018 | Karleen Tichy, 809 Elm St, Suite 1200, Alexandria, MN 56308-5296 Ph: (320) 763-6018 |
News Archive
COPD is defined as a preventable and treatable disease associated with significant extrapulmonary consequences that may contribute to severity. The pulmonary component of COPD is characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive with an abnormal inflammatory response of the lungs to noxious particles (GOLD Strategy Document). Airflow obstruction in COPD is not highly variable and largely irreversible.
Obesity triggers atrial fibrillation in fertile women, according to research presented today at the ESC Congress 2012 by Dr Deniz Karasoy from Denmark.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.
› Verified 8 days ago
Kristi L Wentworth, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 725 Elm St, Suite 1200, Alexandria, MN 56308 Phone: 320-763-6018 Fax: 320-763-4127 | |
Meghan Ruhr, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 111 17th Ave E, Alexandria, MN 56308 Phone: 320-762-1511 | |
Nathan Jeffrey King, APRN, CRNA Registered Nurse Medicare: Medicare Enrolled Practice Location: 111 17th Ave E, Alexandria, MN 56308 Phone: 320-762-1511 | |
Sarah Lyn Feierabend, DNP, CNM Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1527 Broadway St, Alexandria, MN 56308 Phone: 320-762-0399 Fax: 320-762-6828 | |
Karlee Rose Rieland, CNP Registered Nurse Medicare: Medicare Enrolled Practice Location: 111 17th Ave E Ste 101, Alexandria, MN 56308 Phone: 320-335-6062 Fax: 320-762-1935 | |
Joyce Marie Iverson, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 725 Elm St, Suite 1200, Alexandria, MN 56308 Phone: 320-763-6018 Fax: 320-763-4127 | |
Angela Krebs, PHN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 725 Elm St, Suite 1200, Alexandria, MN 56308 Phone: 320-763-6018 Fax: 320-763-4127 |